CETP activity variation in mice does not affect two major HDL antiatherogenic properties: Macrophage-specific reverse cholesterol transport and LDL antioxidant protection

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 505-513

  Rotllan, Noemí ^a   Calpe Berdiel, Laura ^a   Guillaumet Adkins, Amy ^c   Süren Castillo, Songül ^a   Blanco Vaca, Francisco ^b,c   Escolà Gil, Joan Carles ^a  

^a Institut de Recerca   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

CETP; HDL; Macrophages; Paraoxonase; Reverse cholesterol transport

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; DICHLOROFLUORESCEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENIC DIET; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLUORESCENCE; GEL MOBILITY SHIFT ASSAY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, DIETARY; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACACA FASCICULARIS; MACROPHAGES; MICE; MICE, TRANSGENIC;

EID: 38349131657     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.05.007     Document Type: Article

References (45)

1. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
2. Tall A.R. Plasma cholesteryl ester transfer protein. J Lipid Res 34 (1993) 1255-1274
3. de Grooth G.J., Klerkx A.H., Stroes E.S., et al. A review of CETP and its relation to atherosclerosis. J Lipid Res 45 (2004) 1967-1974
4. Forrester J.S., Makkar R., and Shah P.K. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 111 (2005) 1847-1854
5. Klerkx A.H., El Harchaoui K., van der Steeg W.A., et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels. pathways by which modulation of cetp activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 26 (2006) 706-715
6. Agellon L.B., Walsh A., Hayek T., et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 266 (1991) 10796-10801
7. Marotti K.R., Castle C.K., Murray R.W., et al. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice. Arterioscler Thromb 12 (1992) 736-744
8. Escola-Gil J.C., Calpe-Berdiel L., Palomer X., et al. Antiatherogenic role of high-density lipoproteins: insights from genetically engineered-mice. Front Biosci 11 (2006) 1328-1348
9. Marotti K.R., Castle C.K., Boyle T.P., et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364 (1993) 73-75
10. Hayek T., Masucci-Magoulas L., Jiang X., et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 96 (1995) 2071-2074
11. Plump A.S., Masucci-Magoulas L., Bruce C., et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19 (1999) 1105-1110
12. Escola-Gil J.C., Julve J., Marzal-Casacuberta A., et al. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J Lipid Res 42 (2001) 241-248
13. Westerterp M., van der Hoogt C.C., de Haan W., et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26 (2006) 2552-2559
14. Foger B., Chase M., Amar M.J., et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 274 (1999) 36912-36920
15. MacLean P.S., Bower J.F., Vadlamudi S., et al. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice. Arterioscler Thromb Vasc Biol 23 (2003) 1412-1415
16. Linsel-Nitschke P., and Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4 (2005) 193-205
17. Osono Y., Woollett L.A., Marotti K.R., et al. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci USA 93 (1996) 4114-4119
18. Alam K., Meidell R.S., and Spady D.K. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 276 (2001) 15641-15649
19. Harada L.M., Amigo L., Cazita P.M., et al. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 191 (2007) 313-318
20. Brousseau M.E., Diffenderfer M.R., Millar J.S., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25 (2005) 1057-1064
21. Zhang Y., Zanotti I., Reilly M.P., et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108 (2003) 661-663
22. Rotllan N., Ribas V., Calpe-Berdiel L., et al. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 25 (2005) e128-e132
23. Calpe-Berdiel L., Rotllan N., Palomer X., et al. Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Biochim Biophys Acta 1738 (2005) 6-9
24. Moore R.E., Navab M., Millar J.S., et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 97 (2005) 763-771
25. Noto H., Kawamura M., Hashimoto Y., et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis 171 (2003) 131-136
26. Bisoendial R.J., Hovingh G.K., El Harchaoui K., et al. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 25 (2005) e133-e134
27. Zhang B., Fan P., Shimoji E., et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 24 (2004) 1910-1915
28. Huang Z., Inazu A., Nohara A., et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 103 (2002) 587-594
29. Trocho C., Escola-Gil J.C., Ribas V., et al. Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration. Atherosclerosis 174 (2004) 275-285
30. Ribas V., Sanchez-Quesada J.L., Anton R., et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 95 (2004) 789-797
31. Calpe-Berdiel L., Escola-Gil J.C., Ribas V., et al. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis 181 (2005) 75-85
32. Marzal-Casacuberta A., Blanco-Vaca F., Ishida B.Y., et al. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem 271 (1996) 6720-6728
33. Serrat-Serrat J., Ordonez-Llanos J., Serra-Grima R., et al. Marathon runners presented lower serum cholesteryl ester transfer activity than sedentary subjects. Atherosclerosis 101 (1993) 43-49
34. Stein O., Dabach Y., Hollander G., et al. Reverse cholesterol transport in mice expressing simian cholesteryl ester transfer protein. Atherosclerosis 164 (2002) 73-78
35. Cuchel M., and Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 113 (2006) 2548-2555
36. Rader D.J. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 (2006) 3090-3100
37. Masson D., Staels B., Gautier T., et al. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res 45 (2004) 543-550
38. Van Eck M., Ye D., Hildebrand R.B., et al. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ Res 100 (2007) 678-685
39. Zhang Y., Da Silva J.R., Reilly M., et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 115 (2005) 2870-2874
40. Gauthier A., Lau P., Zha X., et al. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 25 (2005) 2177-2184
41. Cazita P.M., Berti J.A., Aoki C., et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res 44 (2003) 33-40
42. Chiang J.Y. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 40 (2004) 539-551
43. Luo Y., and Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105 (2000) 513-520
44. Blanco-Vaca F., Escola-Gil J.C., Martin-Campos J.M., et al. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 42 (2001) 1727-1739
45. Chiba H., Akita H., Kotani K., et al. Complete cholesteryl ester transfer protein deficiency increases oxidized-LDL in plasma. Rinsho Byori 45 (1997) 55-57